Biologic agents for rheumatoid arthritis: 2008 and beyond

Journal of Infusion Nursing

Volumn 32, Issue SUPPL.1, 2009, Pages

  Sweiss, Nadera J ^a   Hushaw, Linda L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; OCRELIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL SUPPRESSION; ALOPECIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE COMPARISON; DRUG ERUPTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MUCOSAL DISEASE; NURSING CARE; NURSING ROLE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT PARTICIPATION; PATIENT SATISFACTION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; ARTICLE; CONTINUING EDUCATION; DRUG ANTAGONISM; NURSE ATTITUDE; NURSING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EDUCATION, CONTINUING; HUMANS; INTERLEUKIN-6; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61749089039     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e318192e311     Document Type: Review

References (59)

1. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill Medical; 2008.
2. Scrivo R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:312-322.
3. Teitelbaum SL. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Research & Therapy. 2006;8(1):201.
4. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12(3):183-189.
5. Jackson CG, Williams HJ. Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. Drugs. 1998;56(3):337-344.
6. Olivieri I, Palazzi C, Peruz G, Padula A. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging. 2005;22(10):809-822.
7. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65(5):661-694.
8. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.
9. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(4)):CD001461.
10. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61-66.
11. van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27(5):345-352.
12. Stowell CP. Therapy with immunoglobulin: applications for monoclonal antibodies. J Infus Nurs. 2006;29(3)(Suppl):S29-S44.
13. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-916.
14. Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol. 2002;28(62):27-35.
15. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193-202.
16. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weissman MH, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50(4):1051-1065.
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
18. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
19. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063-1074.
20. Furst DE, Schiff MH, Fleischmann RM, Strand V, Bibara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563-2571.
21. US Food and Drug Administration. Manufacturers of TNF-blocker drugs must highlight risk of fungal infections. http://www.fda.gov/bbs/topics/NEWS/2008/ NEW01879.html. Accessed September 9, 2008.
22. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci. 2005;1051:716-729.
23. ®) prescribing information. http://www.kineretrx.com/pi.jsp. Accessed August 23, 2008.
24. ®) prescribing information. http://packageinserts.bms.com/pi/pi-orencia.pdf. Accessed August 23, 2008.
25. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
26. ®) prescribing information. http://www.gene.com/gene/products/information/pdf/rituxan- prescribing.pdf. Accessed August 23, 2008.
27. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
28. Keystone E, Mason D, Combe B. The Anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: 1-year results from the RAPID 1 study. Paper presented at: American College of Rheumatology 2007 Annual Meeting; November 6-11, 2007; Boston, MA. Abstract 700.
29. van der Heijde D, Strand V, Keystone E, Landewé R. Inhibition of radiographic progression by lyophilized certolizumab pegol added to methotrexate in comparison with methotrexate alone in patients with rheumatoid arthritis: the RAPID 1 trial. Paper presented at: American College of Rheumatology 2007 Annual Meeting; November 6-11, 2007; Boston, MA. Abstract 940.
30. Smolen J, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent (s): results of the randomized, double-blind, placebo. Paper presented at: The European League Against Rheumatism 2008 Annual Congress; June 11-14, 2008; Paris, France. Abstract OP-0010.
31. Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebocontrolled, dose-ranging study. Arthritis Rheum. 2008;58:2652-2661.
32. Genovese MC, Beaulieu AD, Ramos-Remus C, Davies C, John A, Smolen JS. Efficacy of tocilizumab in combination with DMARDs is superior to DMARDs alone in moderate-to-severe rheumatoid arthritis based on ACR criteria: a pooled analysis of clinical trial data from OPTION and TOWARD. Paper presented at: The European League Against Rheumatism 2008 Annual Congress; June 11-14, 2008; Paris, France. Abstract THU0185.
33. Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol. 2007;34(12):2334-2342.
34. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10)(Suppl 2):S66-S76.
35. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-919.
36. van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Tract Rheumatol. 2007;3(12):681.
37. Barber N, Parsons J, Clifford S, Darracott R, Home R. Patients' problems with new medication for chronic conditions. Qual Saf Health Care. 2004;13(3):172-175.
38. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis. 2001;60(9):869-875.
39. Heller JE, Shadick NA. Outcomes in rheumatoid arthritis: incorporating the patient perspective. Curr Opin Rheumatol. 2007;19(2):101-105.
40. Vizcarra C, Belcher D. Management of the patient receiving parenteral biologic therapy. J Infus Nurs. 2006;29:63-71.
41. Kennedy T, McCabe C, Struthers G, Sinclair H, Chakravaty K, Bax D, et al. BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford). 2005;44(4):553-556.
42. Kjeken I, Dagfinrud H, Mowinckel P, Uhlig T, Kvien TK, Finset A. Rheumatology care: involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 2006;55(3):394-401.
43. Suresh E. Management of early rheumatoid arthritis. J Assoc Phys India. 2007;55:355-362.
44. Nordmark B, Blomqvist P, Andersson B, Hagerstrom M, Nordh-Grate K, Ronnqvist R, et al. A two-year follow-up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational support. Scand J Rheumatol. 2006;35(1):7-14.
45. Mäkelãinen P, Vehviläinen-Julkunen K, Pietilä AM. Rheumatoid arthritis patients' education-contents and methods. J Clin Nurs. 2007;16(11C):258-267.
46. Palmer D, El Gaafary M, El Miedany Y. Improving patient care: measurement of outcome in rheumatoid arthritis. Br J Nurs. 2007;16(16):1010-1015.
47. Stone WJ. Comprehensive nursing approach to infliximab infusion therapy. J Infus Nurs. 2003;26(6):380-387.
48. Harris ED, Schur PH. Overview of the systemic and nonarticular manifestations of rheumatoid arthritis. UpToDate 16.3. http://www. uptodateonline.com/online/index/do. Accessed October 17, 2008.
49. Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum. 2008;58:637-640.
50. Newsome G, American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 update. J Am Acad Nurse Pract. 2002;14(10):432-437.
51. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-784.
52. Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum. 2006;55(6):873-877.
53. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809.
54. ®) prescribing information. http://www.rxabbott.com/pdf/humira.pdf. Accessed October 15, 2008.
55. ®) prescribing information. http://www.enbrel.com/prescribing-information. jsp. Accessed October 15, 2008.
56. ®) medication guide. www.centocor.com/centocor/assets/medication-guide.pdf. Accessed October 15, 2008.
57. Choy EH, Hazleman B, Smith M, Lisi L, Scott DG, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002;41(10):1133-1137.
58. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964-975.
59. Genovese MC, McKay JD, Nasonov EL, Mysler E, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980.